

# Otsuka's Economic Impact in Maryland


Otsuka is a healthcare company driven by its purpose and defined by its beliefs. A leader in central nervous system (CNS) and nephrology, Otsuka provides both pharmaceuticals and digital healthcare solutions. The company has nearly 2,000 employees in the United States.

In Maryland, Otsuka employs nearly 140 people at corporate offices in Rockville. Beyond its direct employment and spending, Otsuka's operations support additional jobs, wages,

and economic activity in the state. In 2022, Otsuka supported more than 900 jobs, generated nearly \$155 million in labor income (a measure of wages), and contributed more than \$291 million in economic output in Maryland. Otsuka's business activities in Maryland also result in additional tax revenues. In 2022, state, local, and federal tax receipts attributable to or supported by Otsuka's economic activity in Maryland are estimated at \$45.7 million.<sup>1</sup> (See Figure 1.)



**FIGURE 1.** Otsuka's Economic and Fiscal Impact in Maryland\*



\* Note: Totals may differ from sum of numbers due to rounding.

<sup>1</sup> These estimates were derived by Matrix Global Advisors (MGA) using a macroeconomic model of the state of Maryland constructed by IMPLAN. A description of the methodology as well as full results of Otsuka's economic impact in the United States are available at <https://www.otsuka-us.com/sites/g/files/qhldwo8366/files/media/static/01US23EBC0006-Otsuka-Economic-Impact-Report.pdf>.



# Otsuka's Products and Therapeutic Areas of Focus



## NEUROSCIENCE

The driving philosophy at Otsuka is to serve those with unmet medical needs, and that couldn't be truer than in Otsuka's dedication to the CNS space. Otsuka is committed to making a difference in the lives of patients living with schizophrenia, major depressive disorder, bipolar disorder, and other CNS conditions.



OAPI co-promotes ABILIFY ASIMTUFII with H. Lundbeck, A/S



OAPI co-promotes REXULTI with H. Lundbeck, A/S



OAPI co-promotes ABILIFY MAINTENA with H. Lundbeck, A/S



## NEPHROLOGY

For more than 20 years, Otsuka has been bringing its research and expertise to this therapeutic area. Otsuka has focused on developing novel drugs in areas of unmet need, such as autosomal dominant polycystic kidney disease and hyponatremia, that have changed the treatment landscape.



## DIGITAL INNOVATION

Digital technology has not only changed the world we live in, but it is also changing the face of healthcare. Otsuka is at the forefront of this transformative juncture in medicine, creating novel solutions that help address the challenges of those living with serious mental illness.



Please see FULL PRESCRIBING INFORMATION including BOXED WARNING(S) for ABILIFY, ABILIFY ASIMTUFII, ABILIFY MAINTENA, ABILIFY MYCITE, JYNARQUE, NUEDEXTA, REXULTI, and SAMSCA at [www.otsuka-us.com/products](http://www.otsuka-us.com/products).

## ABOUT OTSUKA

Founded in Japan in 1921, Otsuka Pharmaceutical Co. Ltd. today has an international network of 200 companies and approximately 47,000 employees in 32 countries and regions. For the purposes of this document, "Otsuka" refers to Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., McQuade Center for Strategic Research & Development, and Otsuka Precision Health, Inc.

This document is a collaboration between Matrix Global Advisors (MGA) and Otsuka.



State-level economic impact estimates produced by MGA using a macroeconomic model of Maryland constructed by IMPLAN.

© 2024 Otsuka America Pharmaceutical, Inc. All rights reserved.

We defy limitation, so that others can too.

